Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Goldman Sachs has reported Q3 results, and the immediate reaction from covering analysts is a fresh round of target reductions that continues a pattern in place for most of October.
The analyst response to the print has been swift and uniform in direction. Citigroup cut its target from $1,050 to $1,000 today while holding a Neutral rating. RBC Capital made the sharpest move, dropping its target from $1,220 to $1,010, also keeping a Sector Perform. Keefe, Bruyette & Woods trimmed from $1,130 to $1,100 at Market Perform. These follow a string of pre-earnings reductions from UBS, Evercore ISI, and Wells Fargo that previous ORTEX notes documented in detail. The consensus mean target now stands at $1,052.67, against a close of $891.91. That gap implies roughly 18% upside, but the direction of travel matters as much as the level: every analyst who moved in the past two weeks moved lower. The buy consensus is intact in name, with six buy ratings on record, yet the tone is one of managed expectations rather than fresh conviction.
Options positioning has shifted since the pre-earnings setup described in the October 10 earnings preview. The put/call ratio has climbed back to 0.80 from the 52-week low of 0.78 recorded in the days before the print, and the 20-day mean is 0.81. The PCR z-score is marginally negative at -0.51, meaning options flow is essentially neutral relative to recent history. The extreme call skew that characterised pre-earnings positioning has faded. Short interest tells a relaxed story throughout: at 2.1% of free float, down 3.4% on the week, there is no meaningful short pressure in the stock. Borrow availability is effectively unconstrained, with over 217 million shares available to lend. Cost to borrow has ticked up 27% on the week to 0.39%, but that figure remains firmly in the negligible range for a stock of this liquidity.
The factor picture is a study in contrasts. Goldman scores in the 89th percentile on EPS surprise and the 90th on analyst recommendation dispersion, reflecting a long track record of beating estimates and wide coverage breadth. Against that, the 12-month forward EPS momentum score has slid to the 11th percentile, a sign the Street has been cutting near-term earnings forecasts steadily. The PE multiple has compressed by roughly 1.2 turns over the past month to 12.4x, and price-to-book has pulled back to 2.27x, also down over 30 days. Valuation is cheaper than a month ago, but the earnings revisions trend is the drag that explains much of the analyst caution. The bull case rests on the wealth and asset management pivot and Goldman's capacity to generate strong returns on equity through a cycle. The bear case points to cyclical headwinds from a lower-rate environment, sustained pressure on traditional capital markets revenue, and regulatory constraints on the business mix.
Among peers, the picture on Tuesday was uniformly weak. MS fell 1.8% on the day and is down 2.3% on the week. EVR dropped 3% in Tuesday's session. IVZ is the week's worst performer in the group, off 4.8%. Goldman's own 0.6% weekly decline looks relatively contained in that company, though the 13.3% one-month decline is a reminder of how much ground the stock has already surrendered.
Goldman's own balance sheet data from FDIC call reports shows net loans and leases rising for nine consecutive quarters, reaching $247.6 billion as of the April 2026 period, and total assets climbing for six straight quarters to $758.8 billion. The FDIC dataset has not yet been tested for a lead relationship against reported net income, so these figures are balance sheet context rather than a forward read on the print.
The stock's ORTEX short score has eased from 33.5 in early October to 33.0 now, a gentle move lower that is consistent with short interest contracting slightly this week. The next earnings event is not until January 19, giving the Street three months to revise further in either direction. What to watch in the interim is whether the target-cutting cycle stabilises near current levels or resumes, and whether the gap between the consensus mean target and the current price narrows through price action, further estimate reductions, or both.
See the live data behind this article on ORTEX.
Open GS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.